MedPath

Clinical study of mahatiktak ghruta and tranexamic acid in dysfunctional uterine bleeding

Phase 3
Conditions
Health Condition 1: N80-N98- Noninflammatory disorders of female genital tract
Registration Number
CTRI/2024/01/061305
Lead Sponsor
Dr Archana Singh
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Any women having age group between 18-45 years complaints of asrygdar.

2.Patients who willing to give consent for this study.

Exclusion Criteria

1. Known case of breast abscess, mastitis, cracked nipples and breast cancer.

2.Pregnancy,lactation,known case of fibroid,adenomyosis,endometriosis.

3. Patients suffering from asrugdar due to secondary cause like HIV, TB.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.To determine the clinical effectiveness of mahatiktak ghruta and tranexamic acid in the management of asrugdar w.s.r to dysfunctional uterine bleeding. <br/ ><br>2. To comapare the effectiveness of mahatiktak ghruta and tranexamic acid in the management of asrugdar w.s.r to dysfunctional uterine bleedingTimepoint: At Baseline, 1st week,2nd week and 3 months
Secondary Outcome Measures
NameTimeMethod
ilTimepoint: Nil
© Copyright 2025. All Rights Reserved by MedPath